Renal cell carcinoma (RCC) is a common tumor that is largely
refractory to cytotoxic agents. With the implementation of a multitude
of novel therapies in the past 10 years, the overall survival of
patients with advanced RCC has more than doubled.
Over the past 10 years, enormous progress has been made in breast
cancer (BC) treatment, leading to a substantial decline in BC
mortality in Western countries. Although the following short review is
necessarily incomplete, the discussion will highlight major
achievements in the field.
An exciting decade of progress—10th anniversary of memo
The past 10 years have been an exciting ride for Chronic Lymphocytic
Leukemia (CLL) aficionados. An overview of changes in management
paradigms in CLL, ranging from insights into biology, via chemotherapy
and chemoimmunotherapy to maintenance and novel drugs will be
Or the publisher’s dilemma how to present a growing complexity of
scientific knowledge to clinicians, helping them to improve their
daily care for their patients
Ten years ago, in spring 2007 a noble lady wearing a queenly
looking hat invited me (WH) to start a new printed journal on
hematology and oncology with a focus on the German-speaking
As Vice-President of the Austrian Society of Hematology and Medical
Oncology, I have the pleasure and honor to congratulate _memo_ on its
10-year anniversary. This international journal for oncology and
hematology professionals now has an established role in the landscape
of clinical hematology and oncology print media.
Spectacular developments in neuro-oncology during the last decade
_Silvia Hofer,_ _Switzerland_
The 2016 World Health Organization Classification of Tumors of the
Central Nervous System introduced for the first time molecular
parameters in addition to histology to define tumor entities.